Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

Inclusion Criteria: * Patient must have suspected intrahepatic or hilar cholangiocarcinoma with minimal extrahepatic disease. Diagnosis must be histologically or cytologically confirmed for continued treatment on study after pump placement. * Patient must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral computed tomography (CT) scan/MRI * Patient must have disease that is unresectable or borderline resectable with \< 70% liver involvement by cancer * Patient must be \>= 18 years old. * Patient's Eastern Cooperative Oncology Group (ECOG) performance status must be =\< 2 (Karnofsky \>= 60%) * Patient must have normal organ and marrow function as defined below: * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 75,000/mcL * Total bilirubin =\< 2 mg/dL * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) =\< 5 X institutional upper limit of normal * Creatinine \<= institutional upper limit normal * Patient must be able to understand and willing to sign a written informed consent document Exclusion Criteria: * Patients must not have had prior treatment with FUDR * Patient must not be receiving any other investigational agents * Patient must not have a diagnosis of Gilbert's disease * …